Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of upadacitinib versus abatacept in biologic-experienced rheumatoid arthritis
MOH_2017-07-12_000315Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Safety and efficacy of upadacitinib versus abatacept. Started May 2017; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on MOH_2017-07-12_000315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-12_000315.